z-logo
open-access-imgOpen Access
Management of Severe Sepsis of Abdominal Origin
Author(s) -
Frederic M. Pieracci,
Philip S. Barie
Publication year - 2007
Publication title -
scandinavian journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.774
H-Index - 50
eISSN - 1799-7267
pISSN - 1457-4969
DOI - 10.1177/145749690709600302
Subject(s) - medicine , septic shock , intensive care medicine , peritonitis , sepsis , organ dysfunction , abdominal surgery , multiple organ dysfunction syndrome , empiric therapy , surgery , pathology , alternative medicine
Severe sepsis is a life-threatening condition that may occur as a sequela of intra-abdominal infections (IAIs) of all types. Diagnosis of IAIs is predicated upon the combination of physical examination and imaging techniques. Diffuse peritonitis usually requires urgent surgical intervention. In the absence of diffuse peritonitis, abdominal computed tomography remains the most useful test for the diagnosis of IAIs, and is essential to both guide therapeutic interventions and evaluate suspected treatment failure in the critically ill patient. Parameters most consistently associated with poor outcomes in patients with IAIs include increased illness severity, failed source control, inadequate empiric antimicrobial therapy, and healthcare-acquired, as opposed to community-acquired infection. Whereas community-acquired IAI is characterized predominantly by enteric gram-negative bacilli and anaerobes that are susceptible to narrow-spectrum agents, healthcare-acquired IAI (e.g., anastomotic dehiscence, postoperative organ-space surgical site infection) frequently involves at least one multi-drug resistant pathogen, necessitating broad-spectrum therapy guided by both culture results and local antibiograms. The cornerstone of effective treatment for abdominal sepsis is early and adequate source control, which is supplemented by antibiotic therapy, restoration of a functional gastrointestinal tract (if possible), and support of organ dysfunction. Furthermore, mitigation of deranged immune and coagulation responses via therapy with recombinant human activated protein C may improve survival significantly in severe cases complicated by septic shock and multiple organ dysfunction syndrome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here